张烜博士, 教授, 博士生导师
专业和研究方向: 药剂学
电话/传真：010-82805928
电子信箱 ： xuanzhang@bjmu.edu.cn
1990、93、99年获中国药科大学药剂专业学士、硕士和博士学位。
1993-6年，中国药科大学药剂教研室任教；
1999-2001年，北京大学药学院从事博士后研究工作；
2001年-至今，北京大学365bet官方网站是多少任教，教授、博士生导师。
期间于2004年至2005在瑞典斯德哥尔摩大学、2006年4月在日本九州大学进行访问研究。
主讲药剂学及高等药剂学等本科及研究生课程。《中国药学》英文版编委。
参加NSF重大、重点及973等科研项目，主持NSF面上项目、863、重大新药创制等科研项目。2003、2008、2015年获北京大学医学部优秀教师奖；获96年度获国家医药管理局科技进步三等奖（第2完成人）、2003年度教育部提名科技进步二等奖（第2完成人）、2008中国药学会科学技术一等奖1项（第2完成人）、2009年度教育部自然科学一等奖（第4完成人）等奖项。
发表论文五十余篇，参编教材五部。授权专利4项。开展多项药物新制剂及新剂型研究。
研究兴趣：
载体给药系统
代表性论文：
1. Liu XR, Wu KC, Huang Y, Sun JB, Ke XY, Wang JC, Lu WL, Zhang X*, Zhang Q. In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull. 2008 Jun; 31(6):1215-20.
2. Huang Y, Chen XM, Zhao BX, Ke XY, Zhao BJ, Zhao X, Wang Y, Zhang X*, Zhang Q. Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo. AAPS PharmSciTech. 2010 May 5; 11(2):752-9.
3. Ke XY, Zhao BJ, Zhao X, Wang Y, Huang Y, Chen XM, Zhao BX, Zhao SS, Zhang X*, Zhang Q. The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. Biomaterials. 2010 Aug; 31(22):5855-64.
4. Zhang X, Ogl？cka K, Sandgren S, Belting M, Esbj？rner EK, Nordén B, Gr？slund A.Dual functions of the human antimicrobial peptide LL-37-Target membrane perturbation and host cell cargo delivery. Biochim Biophys Acta. 2010 Dec; 1798(12):2201-8.
5. Zhao BJ, Ke XY, Huang Y, Chen XM, Zhao X, Zhao BX, Lu WL, Lou JN, Zhang X*, Zhang Q. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J Drug Target. 2011 Jun;19(5):382-90.
6. Jia Z, Lin P, Xiang Y, Wang X, Wang J, Zhang X*, Zhang Q*. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Eur J Pharm Biopharm. 2011 Sep;79(1):126-34.
7. Wang Y, Wu KC, Zhao BX, Zhao X, Wang X, Chen S, Nie SF, Pan WS, Zhang X*, Zhang Q. A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, in vivo anti-tumor efficacy and safety. J Biomed Biotechnol. 2011;2011:854872.
8. Zhao BX, Zhao Y, Huang Y, Luo LM, Song P, Wang X, Chen S, Yu KF, Zhang X*, Zhang Q. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials. 2012 Mar;33(8):2508-20.
9. Zhao S, Dai W, He B, Wang J, He Z, Zhang X*, Zhang Q*. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release. 2012 Mar 28;158(3):413-23.
10. Liu X, Sun J, Chen X, Wang S, Scott H, Zhang X*, Zhang Q. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. J Pharm Pharmacol. 2012 Jun;64(6):775-82.
11. Luo LM, Huang Y, Zhao BX, Zhao X, Duan Y, Du R, Yu KF, Song P, Zhao Y, Zhang X*, Zhang Q. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials. 2013 Jan;34(4):1102-14.
12. Li D, Yang K, Li JS, Ke XY, Duan Y, Du R, Song P, Yu KF, Ren W, Huang D, Li XH, Hu X, Zhang X*, Zhang Q. Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. Int J Nanomedicine. 2012;7:6105-14.
13. Duan Y, Zhao X, Ren W, Wang X, Yu KF, Li D, Zhang X*, Zhang Q. Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation. Onco Targets Ther. 2013;6:189-98.
14. Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X*, Zhang Q. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:2473-85.
15. Du R Zhong T, Zhang WQ, Song P, Song WD, Zhao Y, Wang C, Tang YQ, Zhang X*, Zhang Q. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. Int J Nanomedicine. 2014 Jun 24;9:3091-3105.
16. Wang C, Wang X, Zhong T, Zhao Y, Zhang WQ, Ren W, Huang D, Zhang S, Guo Y, Yao X, Tang YQ, Zhang X*, Zhang Q. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo. Int J Nanomedicine. 2015 Mar 19;10:2229-48.
17. Zhang WQ, Yu KF, Zhong T, Luo LM, Du R, Ren W, Huang D, Song P, Li D, Zhao Y, Wang C, Zhang X*. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL? J Drug Target. 2015 Dec;23(10):897-909.
18. Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, Yao X, Wang C, Zhang WQ, Zhang X*, Zhang Q. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Control Release. 2016 Jan 28;222:56-66.
19. Huang D, Zhang S, Zhong T, Ren W, Yao X, Guo Y, Duan XC, Yin YF, Zhang SS, Zhang X*. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy. Oncotarget. 2016 Jul 12;7(28):43616-43628.
20. Song P, Yao X, Zhong T, Zhang S, Guo Y, Ren W, Huang D, Duan XC, Yin YF, Zhang SS, Zhang X*. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug. Oncotarget. 2016 Jul 26;7(30):48467-48480.
21. Zhong T, Yao X, Zhang S, Guo Y, Duan XC, Ren W, Dan Huang, Yin YF, Zhang X*. A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic. Sci Rep. 2016 Nov 4;6:36614.
22. Guo Y, Zhong T, Duan XC, Zhang S, Yao X, Yin YF, Huang D, Ren W, Zhang Q, Zhang X*. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix. Drug Deliv. 2017 Nov;24(1):270-277.
23. Yin YF, Guo Y, Song WD, Duan XC, Zheng XC, Zhong T, Zhang S, Yao X, Xu MQ, Zhang Q, Zhang X*. Improving Solubility and Oral Bioavailability of Febuxostat by Polymer-Coated Nanomatrix. AAPS PharmSciTech. 2017 Oct 27. doi: 10.1208/s12249-017-0905-z.
24. Zhong T, Hao YL, Yao X, Zhang S, Duan XC, Yin YF, Xu MQ, Guo Y, Li ZT, Zheng XC, Li H, Zhang X*. The effect of XlogP and Hansen solubility parameters on small molecule modified paclitaxel anti-cancer drug conjugates self-assembled into nanoparticles. Bioconjug Chem. 2018 Jan 4. doi: 10.1021/acs.bioconjchem.7b00767.
